Tanja Lahaye

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Andreas Hochhaus, Sebastian Kreil, A. Corbin et al. · Leukemia · 2002 · 900 citations

Chromatin, Genome Instability, Cell Division +9

Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center

Tanja Lahaye, Birte Riehm, Ute Berger et al. · Cancer · 2005 · 226 citations

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α

Kirsten Merx, M. C. Muller, Sebastian Kreil et al. · Leukemia · 2002 · 171 citations

Hematological Malignancy, Chromatin Structure, Epigenetic Regulation +11

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Rüdiger Hehlmann, Ute Berger, Markus Pfirrmann et al. · Blood · 2007 · 168 citations · Full text

Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

Andreas Burchert, Stefan Wölfl, Manuel Schmidt et al. · Blood · 2002 · 135 citations · Full text